Outcomes that work - improving end of life experience for patients and providers while reducing funder waste

Alignd is a value based care company with an end-to-end serious cancer / palliative care product as first working example.

1612 patients have been or are under care since Alignd started in Aug 2019.

Future developments in chronic kidney disease and maternity are under consideration.

Alignd patients are compared to other oncology patients qualifying for palliative care.

Alignd did not find a complete list of relevant ICROM measures, but built on the ICHOM application of PROMs and PREMs. Clearly defining the right measures in close collaboration with the providers of the coalface and generating the data is key.

At 60, Solly was diagnosed with terminal lung cancer.

Margaret’s cancer journey without Alignd

She underwent surgery, radiotherapy and two intense courses of chemotherapy over a 12-month period. But her cancer didn’t respond to the chemotherapy as expected. Her oncologist suggested third line chemotherapy, although she would have to pay a significant amount from her own pocket for the treatment, as her oncology benefit on her medical aid was depleted. But Margaret was getting weaker and struggling with severe pain, and she had to stop working.

Solly’s journey on medical aid with an Alignd-partnered scheme

Solly underwent surgery to alleviate some of his symptoms. Doctors recommended chemotherapy with a long-term in-hospital plan. Solly did not want to spend his final days in hospital. He chose to receive home-based care that helped him remain comfortable. He was surrounded by his family in his last days.

Dr Nomalungelo Nyathi
Alignd Firestarter (CEO)
lungi@alignd.co.za

Alignd Pty Ltd
www.alignd.co.za